Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1 6Phase 1/2 2

Status

Withdrawn 2Recruiting 2Completed 2

Sponsor Class

OTHER 6

Study Type

Interventional 6

Sponsor

Cancer Type

Plasma cell 6

Conditions

Glioblastoma 7Multiple Myeloma 6Lymphoma, B-Cell 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Lymphoma, Follicular 5Leukemia, Lymphocytic, Chronic, B-Cell 5Recurrence 4Lymphoma, Mantle-Cell 4Lymphoma, Large B-Cell, Diffuse 4Leukemia, Myeloid, Acute 4Burkitt Lymphoma 4Prostatic Neoplasms 3Lymphoma, Non-Hodgkin 3Glioma 3Astrocytoma 3Sarcoma 2Melanoma 2Lymphoma 2Triple Negative Breast Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Neuroblastoma 1Neoplasms, Plasma Cell 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Metastatic Hormone-Sensitive Prostate Cancer 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Prolymphocytic, B-Cell 1Leukemia, B-Cell 1Leukemia 1

Interventions

Dexamethasone 129Lenalidomide 70Cyclophosphamide 70Bortezomib 69Calcium Dobesilate 50fludarabine 44pomalidomide 40daratumumab 37carfilzomib 33fludarabine phosphate 31Melphalan 25dexamethasone acetate 20dexamethasone 21-phosphate 20auricularum 18Filgrastim 18Whole-Body Irradiation 14Biopsy 13isatuximab 12Vorinostat 12Tacrolimus 12Peripheral Blood Stem Cell Transplantation 12Magnetic Resonance Spectroscopy 12Granulocyte Colony-Stimulating Factor 12Specimen Handling 11Sirolimus 11ixazomib 10belantamab mafodotin 10Panobinostat 10Mycophenolic Acid 10Cyclosporine 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 1 × Multiple Myeloma × Leukapheresis × Clear all
NCT03710421 2026-04-15

CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma

City of Hope Medical Center

Phase 1 Recruiting
30 enrolled
Plasma cell

Multiple Myeloma

NCT07340853 2026-03-10

CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma

University of California, San Francisco

Phase 1 Recruiting
30 enrolled
Plasma cell

Multiple Myeloma

NCT05950113 2024-05-01

CART-BCMA/CS1 in Treating Patients With Relapsed or Refractory Multiple Myeloma

Jonsson Comprehensive Cancer Center

Phase 1 Withdrawn
Plasma cell

Multiple Myeloma

NCT03338972 2023-09-08

Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma

Fred Hutchinson Cancer Center

Phase 1 Completed
28 enrolled 18 charts
Plasma cell

Multiple Myeloma

NCT03506802 2020-07-24

NYSCT MM

Jonsson Comprehensive Cancer Center

Phase 1 Withdrawn
Plasma cell

Multiple Myeloma

NCT00089453 2012-04-19

Study of KIR-Ligand Mismatched Haplo-Identical Natural Killer Cells Transfused Before Autologous Stem Cell Transplant

University of Arkansas

Phase 1 Completed
10 enrolled
Plasma cell

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡